Next Article in Journal
ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia.
Previous Article in Journal
Maturing iPSC-Derived Cardiomyocytes
Open AccessFeature PaperArticle

Characterization of Mesenchymal Stem Cells Derived from Patients with Cerebellar Ataxia: Downregulation of the Anti-Inflammatory Secretome Profile

1
Brain Science & Engineering Institute, School of Medicine, Kyungpook National University, Daegu 41944, Korea
2
Department of Pharmacology and Biomedical Science, School of Medicine, Kyungpook National University, Daegu 41944, Korea
3
Neurodegenerative Diseases Research Group, Korea Brain Research Institute, Daegu 41062, Korea
4
School of Life Sciences, BK21 plus KNU Creative BioResearch Group, Kyungpook National University, Daegu 41566, Korea
5
Bioengineering Institute, Corestem Inc., Seoul 13486, Korea
6
Department of Neurology, Kyungpook National University Chilgok Hospital, Daegu 41404, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2020, 9(1), 212; https://doi.org/10.3390/cells9010212
Received: 13 December 2019 / Revised: 10 January 2020 / Accepted: 10 January 2020 / Published: 15 January 2020
(This article belongs to the Special Issue Neuroinflammation in Neurodegenerative and Neurological Diseases)
Mesenchymal stem cell (MSC) therapy is a promising alternative approach for the treatment of neurodegenerative diseases, according to its neuroprotective and immunomodulatory potential. Despite numerous clinical trials involving autologous MSCs, their outcomes have often been unsuccessful. Several reports have indicated that MSCs from patients have low capacities in terms of the secretion of neurotrophic or anti-inflammatory factors, which might be associated with cell senescence or disease severity. Therefore, a new strategy to improve their capacities is required for optimal efficacy of autologous MSC therapy. In this study, we compared the secretory potential of MSCs among cerebellar ataxia patients (CA-MSCs) and healthy individuals (H-MSCs). Our results, including secretome analysis findings, revealed that CA-MSCs have lower capacities in terms of proliferation, oxidative stress response, motility, and immunomodulatory functions when compared with H-MSCs. The functional differences were validated in a scratch wound healing assay and neuron-glia co-cultures. In addition, the neuroprotective and immunoregulatory protein follistatin-like 1 (FSTL1) was identified as one of the downregulated proteins in the CA-MSC secretome, with suppressive effects on proinflammatory microglial activation. Our study findings suggest that targeting aspects of the downregulated anti-inflammatory secretome, such as FSTL1, might improve the efficacy of autologous MSC therapy for CA. View Full-Text
Keywords: antiinflammation; cerebellar ataxia; mesenchymal stem cells antiinflammation; cerebellar ataxia; mesenchymal stem cells
Show Figures

Figure 1

MDPI and ACS Style

Kim, J.-H.; Han, J.; Seo, D.; Yoon, J.H.; Yoon, D.; Hong, J.; Kim, S.R.; Kim, M.S.; Lee, T.Y.; Kim, K.S.; Ko, P.-W.; Lee, H.-W.; Suk, K. Characterization of Mesenchymal Stem Cells Derived from Patients with Cerebellar Ataxia: Downregulation of the Anti-Inflammatory Secretome Profile. Cells 2020, 9, 212.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop